文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症COVID-19与细菌性脓毒症急性肾损伤的肾脏组织病理学与基因表达谱比较

Comparison of renal histopathology and gene expression profiles between severe COVID-19 and bacterial sepsis in critically ill patients.
PubMed 文献 · Crit Care · 2021-06-10
一句话结论COVID-19相关AKI尸检肾组织表现为更严重急性肾小管坏死和微血管血栓、炎症轻微,但样本量小且活检时间不同,需进一步研究。

该研究对COVID-19(n=6)和细菌性脓毒症(n=27)患者的死后肾活检进行组织病理学和mRNA分析,对照为全肾切除的正常肾组织(n=12)。COVID-19患者ICU入住至活检平均30天,细菌性脓毒症为3-4天。COVID-19-AKI肾活检未检出SARS-CoV-2 RNA(同一患者肺组织PCR阳性),广泛急性肾小管坏死和管周血栓是区别于细菌性脓毒症-AKI的显著组织病理学特征。COVID-19肾组织炎症和内皮活化标志物无变化,提示缺乏肾脏炎症;内皮完整性标志物CD31、PV-1和VE-钙黏蛋白与对照无差异,而细菌性脓毒症患者升高。作者结论认为COVID-19与更严重急性肾小管坏死和微血管血栓形成相关,微血管血流减少但炎症轻微,需进一步研究以确定这些观察是真正的病理生理差异还是与疾病发作后活检时间相关。

要点

  • COVID-19-AKI尸检肾组织未检出SARS-CoV-2 RNA,但同一患者肺组织PCR阳性。
  • 广泛急性肾小管坏死和管周血栓是COVID-19-AKI区别于细菌性脓毒症-AKI的显著组织病理学特征。
  • COVID-19肾组织炎症和内皮活化标志物无变化,提示缺乏肾脏炎症。
  • COVID-19肾组织Tie2 mRNA低表达(倍数变化0.33,p=0.037)及VEGFR2/VEGFR3比值紊乱(倍数变化0.09,p<0.0001),提示微血管血流减少。
  • COVID-19患者ICU入住至活检平均30天,细菌性脓毒症为3-4天,样本量小(COVID-19 n=6),需进一步研究。

适用人群与场景

  • 重症COVID-19合并急性肾损伤(AKI)患者(n=6)及细菌性脓毒症合并AKI患者(n=27),死后30分钟内采集肾活检。
  • 正常对照肾组织来自接受全肾切除术的患者(n=12)。

研究设计与关键结果

  • 研究类型为死后肾活检的组织病理学和mRNA分析,COVID-19患者n=6,细菌性脓毒症患者n=27,正常对照n=12;COVID-19患者ICU入住至活检平均30天,细菌性脓毒症患者为3-4天。
  • COVID-19-AKI肾活检未检出SARS-CoV-2 RNA,而同一患者肺组织PCR阳性。
  • 与细菌性脓毒症-AKI相比,COVID-19-AKI的显著组织病理学特征为广泛急性肾小管坏死和管周血栓。
  • ACE2 mRNA水平在COVID-19(倍数变化0.42,p=0.0002)和细菌性脓毒症(倍数变化0.24,p<0.0001)患者均低于对照。
  • 损伤标志物NGAL和KIM-1 mRNA水平与对照组织相比无变化,但在脓毒症-AKI患者中升高。
  • COVID-19肾组织炎症和内皮活化标志物无变化,提示缺乏肾脏炎症;内皮完整性标志物CD31、PV-1和VE-钙黏蛋白与对照无差异,而细菌性脓毒症患者升高(CD31倍数变化2.3,p=0.0006;PV-1倍数变化1.5,p=0.008)。
  • 血管生成素-1 mRNA水平在COVID-19(倍数变化0.27,p<0.0001)和细菌性脓毒症(倍数变化0.67,p<0.0001)患者均低于对照。
  • COVID-19肾组织Tie2 mRNA低表达(倍数变化0.33,p=0.037)及VEGFR2/VEGFR3比值紊乱(倍数变化0.09,p<0.0001),提示微血管血流减少。

证据类型、等级与局限

  • 证据类型:死后肾活检的组织病理学和mRNA分析研究。
  • 局限:作者指出这是小样本COVID-19患者队列(n=6);COVID-19患者ICU入住至活检平均30天而细菌性脓毒症为3-4天,需进一步研究以确定这些观察是真正的病理生理差异还是与疾病发作后活检时间相关。

对床旁实践的改变

  • 作者认为,COVID-19-AKI与更严重急性肾小管坏死和微血管血栓形成相关,微血管血流减少但炎症轻微。
  • 作者指出,需进一步研究以确定这些观察是真正的病理生理差异还是与疾病发作后活检时间相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The mechanisms driving acute kidney injury (AKI) in critically ill COVID-19 patients are unclear. We collected kidney biopsies from COVID-19 AKI patients within 30 min after death in order to examine the histopathology and perform mRNA expression analysis of genes associated with renal injury.

METHODS: This study involved histopathology and mRNA analyses of postmortem kidney biopsies collected from patients with COVID-19 (n = 6) and bacterial sepsis (n = 27). Normal control renal tissue was obtained from patients undergoing total nephrectomy (n = 12). The mean length of ICU admission-to-biopsy was 30 days for COVID-19 and 3-4 days for bacterial sepsis patients.

RESULTS: We did not detect SARS-CoV-2 RNA in kidney biopsies from COVID-19-AKI patients yet lung tissue from the same patients was PCR positive. Extensive acute tubular necrosis (ATN) and peritubular thrombi were distinct histopathology features of COVID-19-AKI compared to bacterial sepsis-AKI. ACE2 mRNA levels in both COVID-19 (fold change 0.42, p = 0.0002) and bacterial sepsis patients (fold change 0.24, p < 0.0001) were low compared to control. The mRNA levels of injury markers NGAL and KIM-1 were unaltered compared to control tissue but increased in sepsis-AKI patients. Markers for inflammation and endothelial activation were unaltered in COVID-19 suggesting a lack of renal inflammation. Renal mRNA levels of endothelial integrity markers CD31, PV-1 and VE-Cadherin did not differ from control individuals yet were increased in bacterial sepsis patients (CD31 fold change 2.3, p = 0.0006, PV-1 fold change 1.5, p = 0.008). Angiopoietin-1 mRNA levels were downregulated in renal tissue from both COVID-19 (fold change 0.27, p < 0.0001) and bacterial sepsis patients (fold change 0.67, p < 0.0001) compared to controls. Moreover, low Tie2 mRNA expression (fold change 0.33, p = 0.037) and a disturbed VEGFR2/VEGFR3 ratio (fold change 0.09, p < 0.0001) suggest decreased microvascular flow in COVID-19.

CONCLUSIONS: In a small cohort of postmortem kidney biopsies from COVID-19 patients, we observed distinct histopathological and gene expression profiles between COVID-19-AKI and bacterial sepsis-AKI. COVID-19 was associated with more severe ATN and microvascular thrombosis coupled with decreased microvascular flow, yet minimal inflammation. Further studies are required to determine whether these observations are a result of true pathophysiological differences or related to the timing of biopsy after disease onset.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Volbeda M, Jou-Valencia D, van den Heuvel MC, et al. Comparison of renal histopathology and gene expression profiles between severe COVID-19 and bacterial sepsis in critically ill patients. Crit Care. 2021. PMID: 34112226. doi:10.1186/s13054-021-03631-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。